Business
Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results
CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.6 million, or $0.42 per diluted share, on net sales of $34.8 million for the second quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the second quarter of the prior fiscal year. Net sales during the three months
About this update from Natural Alternatives International, Inc.
[{"type":"image","alt":"Natural Alternatives International Inc","displaySize":"","headline":null,"caption":"Natural Alternatives International Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/4f3e1356662d6b44cb17ad390e90dedf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jD6TFBV9nBhhlhndwfuCdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4f3e1356662d6b44cb17ad390e90dedf","width":300,"height":108}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.6 million, or $0.42 per diluted share, on net sales of $34.8 million for the second quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the second quarter of the prior fiscal year.","length":475,"tagName":"p"},{"type":"text","content":"Net sales during the three months ended December 31, 2025, increased $0.7 million, or 2%, to $34.8 million as compared to $34.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 2% to $32.8 million. Private-label contract manufacturing sales increased primarily due to increased orders from several of our existing customers and shipments to new customers, partially offset by decreased shipments to other existing customers.","length":506,"tagName":"p"},{"type":"text","content":"CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 13% to $2.0 million during the second quarter of fiscal year 2026, as compared to $1.8 million for the second quarter of fiscal year 2025. The increase was primarily due to increased raw material orders from existing customers partially offset by a decrease in royalty and licensing revenue.","length":379,"tagName":"p"},{"type":"text","content":"Our net loss for the six months ended December 31, 2025, was $2.8 million, or $0.47 per diluted share, compared to a net loss of $4.2 million, or $0.70 per diluted share, for the six months ended December 31, 2024.","length":214,"tagName":"p"},{"type":"text","content":"Net ...